共 66 条
[1]
Munshi NC(2017)Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis JAMA Oncol 3 28-35
[2]
Avet-Loiseau H(2008)Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation Blood 112 4017-23
[3]
Rawstron AC(2014)High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial): a randomised, open-label, phase 3 trial. Lancet Oncol 15 874-85
[4]
Owen RG(2016)The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial Lancet Haematol 3 e340-351
[5]
Child JA(2013)Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study J Clin Oncol J Am Soc Clin Oncol 31 2540-7
[6]
Thakurta A(2015)Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics’ impact on survival Leukemia 29 689-95
[7]
Paiva B(2018)Improvement in overall survival with carfilzomib, lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma J Clin Oncol J Am Soc Clin Oncol 36 728-34
[8]
Vidriales M-B(2016)Oral ixazomib, lenalidomide and dexamethasone for multiple myeloma N Engl J Med 374 1621-34
[9]
Cervero J(2017)Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma Blood 130 974-81
[10]
Mateo G(2015)The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma Haematologica 100 e53-55